BRIT J HAEMATOL

Diffuse large B- cell lymphoma (DLBCL) patients with relapsed or refractory (RR) disease have poor outcomes with current salvage regimens. We conducted a phase 2 trial to analyse the safety and efficacy of adding lenalidomide to R- ESHAP (LR-ESHAP) in patients with RR DLBCL. Subjects received 3 cycles of lenalidomide 10 mg/ day on days 1- 14 of every 21-day cycle, in combination with R- ESHAP at standard doses. Responding patients underwent autologous stem- cell transplantation (ASCT). The primary endpoint was the overall response rate (ORR) after 3 cycles. Centralized cell- of-origin (COO) classification was performed. Forty- six patients were included. The ORR after LR- ESHAP was 67% (35% of patients achieved complete remission). Patients with primary refractory disease (n = 26) had significantly worse ORR than patients with non-refractory disease (54% vs. 85%, p = 0.031). No differences in response rates according to the COO were observed. Twenty- eight patients (61%) underwent ASCT. At a median follow- up of 41 months, the estimated 3- year PFS and OS were 42% and 48%, respectively. The most common grade =3 adverse events were thrombocytopenia (70% of patients), neutropenia (67%) and anaemia (35%). There were no treatment-related deaths during LR- ESHAP cycles. In conclusion, LR-ESHAP is a feasible salvage regimen with promising efficacy results for patients with RR DLBCL.